SR
Surrozen, Inc.
SRZN · NASDAQ
$16.93 -4.89% (-$0.87)
1M -29.46%
Market Cap $126.6M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$14.52
14.2% downside
Current Price
$16.93
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SRZN is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/S 11.00x
PEG N/A
P/B N/A
Growth
0 /100
Declining Rev. growth 34.72%
FCF growth N/A
Book val. growth N/A
Profitability
20 /100
Weak Net margin 2,885.33%
Op. margin 385.28%
FCF margin 303.92%
Quality
2 /100
Poor ROA 287.30%
Asset turnover 0.10x
ROIC 40.84%
Debt
100 /100
Low Current ratio 12.14x
Int. coverage N/A
Net debt/EBITDA N/A
Stability
65 /100
Moderate EPS volatility 24.83%
Profitable years 0
Beta 0.56x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SRZN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Craig C. Parker
Employees
44
Headquarters
South San Francisco
Upcoming events
06 NOV
Earnings
Upcoming earnings report